Insights on the Retinal Surgery Devices Global Market to 2026 - Featuring Lumenis, Nidek and Optos Among Others
16 août 2021 08h33 HE
|
Research and Markets
Dublin, Aug. 16, 2021 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Insights on the Vision Care Global Market to 2026 - by Product Type, Distribution Channel and Region
01 juil. 2021 08h18 HE
|
Research and Markets
Dublin, July 01, 2021 (GLOBE NEWSWIRE) -- The "Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's...
Global Ophthalmics Partnering Directory 2014-2021: Deals and Contract Documents for Over 550 Ophthalmics Deals
31 mai 2021 04h23 HE
|
Research and Markets
Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "Global Ophthalmics Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. The Global...
ONL Therapeutics Names Connie Chang as Chief Operating Officer
19 janv. 2021 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Jan. 19, 2021 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications
22 déc. 2020 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
Outlook on the Retinal Surgery Devices Global Market to 2025 - by Equipment Type, Application, End-use and Region
01 déc. 2020 06h43 HE
|
Research and Markets
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Retinal Surgery Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to...
ONL Therapeutics Announces First Patient Treated in Phase I Study with ONL1204
23 oct. 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Announces First-In-Human Clinical Study with ONL1204
08 oct. 2019 07h00 HE
|
ONL Therapeutics
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 11h54 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
ONL Therapeutics Raises $3 Million in a Convertible Note to Advance ONL1204 into First-In-Human Clinical Study
22 août 2019 07h00 HE
|
ONL Therapeutics
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...